Global Tumor Immune Cell Therapy Market Growth (Status and Outlook) 2024-2030

Global Tumor Immune Cell Therapy Market Growth (Status and Outlook) 2024-2030

Cancer immune cell therapy is a treatment method that activates the function of the patient's own immune cells, thereby enhancing the immune cells' ability to attack cancer and inhibit cancer cells. In actual treatment, we extract immune cells involved in attacking cancer from the patient's blood, cancer tissue, ascites, and pleural effusion, proliferate, activate, and enhance their functions in vitro before returning them to the patient.

The global Tumor Immune Cell Therapy market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Tumor Immune Cell Therapy Industry Forecast” looks at past sales and reviews total world Tumor Immune Cell Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Tumor Immune Cell Therapy sales for 2023 through 2029. With Tumor Immune Cell Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tumor Immune Cell Therapy industry.

This Insight Report provides a comprehensive analysis of the global Tumor Immune Cell Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Tumor Immune Cell Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tumor Immune Cell Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor Immune Cell Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor Immune Cell Therapy.

United States market for Tumor Immune Cell Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Tumor Immune Cell Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Tumor Immune Cell Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Tumor Immune Cell Therapy players cover MEDINET Co, Erytech, Seta Clinic Group, Takeda, SBI Holdings, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Immune Cell Therapy market by product type, application, key players and key regions and countries.

Segmentation by Type:
Immune Checkpoint Inhibitors
Chimeric Antigen Receptor T-cell Therapy
Tumor-Infiltrating Lymphocytes Therapy
Cancer Vaccines
Bispecific Antibodies
Cytokine Therapy

Segmentation by Application:
Hematological Tumors
Solid Tumors

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Immune Checkpoint Inhibitors
Chimeric Antigen Receptor T-cell Therapy
Tumor-Infiltrating Lymphocytes Therapy
Cancer Vaccines
Bispecific Antibodies
Cytokine Therapy

Segmentation by Application:
Hematological Tumors
Solid Tumors

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
MEDINET Co
Erytech
Seta Clinic Group
Takeda
SBI Holdings
Oxford BioTherapeutics
Fate Therapeutics
Gilead Sciences
Novartis
Osiris
Vericel Corporation
Fujifilm Cellular Dynamics
JCR Pharmaceuticals
Beike Biotechnology
Golden Meditech
Guanhao Biotech
Beroni Group
Legend Biotech

Please note: The report will take approximately 2 business days to prepare and deliver.